The whitepaper explains these key challenges:
Only 20% of medical devices have been certified under the new MDR, with deadlines looming. An NB is an organization designated by an EU Member State to assess the conformity of certain products before being placed on the market. The shortage of NBs is causing delays in market access for U.S. exporters.
The new MDR is highly complex, leading to continuous extensions of implementation deadlines. This ever-increasing complexity makes compliance challenging and unpredictable for MedTech exporters.
Due to these stringent regulations, approximately 15,000 medical devices have been withdrawn from the EU market. This withdrawal limits patient access to critical medical devices.
Certification fees by EU NBs can average $100,000, but reach much higher, compared to the U.S. FDA’s annual registration fee of $6,493. These high costs are driving small and medium-sized U.S. companies out of the EU market. NBs are for-profit agencies and lack the capacity to cover their existing client base, driving costs up.
The MDR mandates recertification every three to five years, even if the device has not changed, further adding to the financial and administrative burden on manufacturers.
The DEC whitepaper explains these challenges in more detail and offers several recommendations to address what is increasingly being viewed as a non-tariff trade barrier. You can read the full whitepaper here: EU Medical Device Regulations: Lack of Certification Resources, Exorbitant Fees, and Slow Standards-Harmonization Impede U.S.-EU Trade.
Like what you read? Join thousands of exporters and importers who subscribe to Passages: The International Trade Blog. You'll get the latest news and tips for exporters and importers delivered right to your inbox.